SPONSOR

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Total Trials

Recruiting

Phases

N/A

Conditions studied: Life-threatening Infection Hepatocellular Carcinoma (HCC)Hepatitis Myeloid Leukemia, Acute Prostate Cancer (Adenocarcinoma)Preeclampsia Hypertensive Disorder of Pregnancy Obesity and Obesity-related Medical Conditions Cardiovascular Risk Genetics

IRCCS Azienda Ospedaliero-Universitaria di Bologna is a clinical research sponsor with 37 registered studies on ClinicalTrials.gov, of which 37 are actively recruiting participants. Research covers conditions including Life-threatening Infection, Hepatocellular Carcinoma (HCC), Hepatitis, Myeloid Leukemia, Acute.

Studies span multiple clinical phases, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — IRCCS Azienda Ospedaliero-Universitaria di Bologna

How many clinical trials has IRCCS Azienda Ospedaliero-Universitaria di Bologna sponsored?

ClinicalMetric currently tracks 37 clinical trials sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna, of which 37 are actively recruiting participants. These trials cover conditions including Life-threatening Infection, Hepatocellular Carcinoma (HCC), Hepatitis. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does IRCCS Azienda Ospedaliero-Universitaria di Bologna research focus on?

IRCCS Azienda Ospedaliero-Universitaria di Bologna clinical trials span Life-threatening Infection, Hepatocellular Carcinoma (HCC), Hepatitis, Myeloid Leukemia, Acute, Prostate Cancer (Adenocarcinoma), and additional conditions. Sponsor focus areas evolve as trials complete and new programs launch.

How do I participate in a IRCCS Azienda Ospedaliero-Universitaria di Bologna clinical trial?

To participate in a IRCCS Azienda Ospedaliero-Universitaria di Bologna trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all IRCCS Azienda Ospedaliero-Universitaria di Bologna trials with current recruitment status updated daily.

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Frequently Asked Questions — IRCCS Azienda Ospedaliero-Universitaria di Bologna

Clinical Trials by IRCCS Azienda Ospedaliero-Universitaria di Bologna

Life-threatening Infection in Humans: from Epidemiological Analysis to Molecular Genetics

Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma

Acute Hepatitis in Pediatrics

Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments

Assessment of ADC Values and Radiomics Characteristics With a MRI of the Prostate to Identify Tumor Lesions

Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy

Cardiometabolic Risk of Obese Subjects: Cross-sectional Study

Nephrological Outcome and Associated Congenital Anomalies in Pediatric Patients with Horseshoe Kidney

The Role of the Vascular Surgeon in Orthopedic Surgery of Musculoskeletal Tumors

Soft Tissue Prediction in Orthognathic Surgery by Making Anatomically Accurate Virtual Model

The Evaluation of Molecular Markers From PRedittivI DNA of Clinical Outcomes in Patients With UROthelial Tumor

Development of a Predictive Model of Fetal PH At Birth from Novel Variables Derived from Cardiotocographic Tracing

PREdiction of succeSSful weanING From Continuous Renal Replacement Theraphy: the Possible Role of Delta C-cistatin

Efficacy of Isatuximab-based Regimens in Relapsed/Refractory Multiple Myeloma With 1q21+

Patients With Tuberculosis, Mycobacteriosis or Latent Tuberculosis

Italian Study of Patients With Lymphoma

PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE

Reliability and Validation of the WB-MRI Radiological Score in CRMO

Implementation of Solid Digital PCR to Support Gold-standard Methods for Evaluation of HER2 Amplification Status: Focus on HER2-low Subtype

Role of Mesh in Laparoscopic Sacropexy Surgical Techniques for the Treatment of Female Genital Prolapse

Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma

Observational Study to Develop a Predictive Score for Adverse Events Post ERCP

Thyroid Carcinoma in Cancer Patients Undergoing Radiotherapy

Intra Artherial Therapies in Treatment of Primary Liver Diseases: an Observational Study

Tissue Analysis of Liver Grafts as a Predictor of Transplant Outcome.

Cryopreservation of Ovarian Tissue: Reimplantation Rate and Effects on Ovarian Function

Visceral Leishmaniasis in Emilia-Romagna (Leishmania-2019)

Evaluation of the Correlation Between Vein Size Inferior Cava and Right Atrial Pressure in Pediatric Age and Creation of a Possible Predictive Model

Respiratory Exacerbations in Children With Bronchopulmonary Dysplasia (BPD): A Case-Control Study

TreaT-Assay: the New Frontier for the Diagnosis of Acute Rejection in Kidney Transplantation

Patients With Diabetes Mellitus on Drug Treatment on the List or Already Undergoing Orthotopic Liver Transplantation

Preoperative Boost Associated With Neoadjuvant Chemotherapy in Luminal B Breast Cancer

Survey for Parental Perception of Procedural Analgosedation in Pediatric Age.

National Epidemiology of Cutaneous Lymphomas

Comparison of Levothyroxine Formulations in the Treatment of Congenital Hypothyroidism

Molecular-genetic Characterization in Patients Undergoing CAR-T Cell Infusion

Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple Myeloma